Navigation Links
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
Date:10/12/2007

provide data to establish forodesine HCL as a new treatment alternative for CTCL patients who have not responded to currently available therapies."

"Initiation of this pivotal trial is a great step forward toward our goal of getting our late-stage pipeline products to market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.

Forodesine HCL is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). In addition to CTCL, the drug is currently being studied in clinical trials for indications including T and B- cell leukemia (T-ALL, B-ALL), and chronic lymphocytic leukemia (CLL).

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including forodesine HCL in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCL in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forwar
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
2. Malvern initiates European user group meetings for chemical imaging
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Team Health Holdings ... the largest suppliers of outsourced healthcare professional staffing and ... the United States , today announced ... Annual Deutsche Bank Healthcare Conference held on May 29, ... begin at 8:00 AM eastern time.  Interested investors and ...
(Date:5/22/2013)... May 22, 2013  The Leukemia & Lymphoma Society ... Valor Biotherapeutics, LLC, a joint venture between ImmunGene and ... and a Phase I clinical trial for a novel ... by many patients with indolent lymphomas who do not ... Valor,s protein, IGN002, is a new class of biotherapeutics ...
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine Technology:Team Health Holdings Inc. to Present at the 38th Annual Deutsche Bank Healthcare Conference 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
(Date:5/22/2013)... that bicyclists who wear helmets have an 88 percent ... Children,s Hospital found that simply having bicycle helmet laws ... and injuries for children younger than 16 who were ... study, conducted by William P. Meehan III, MD, Lois ... of Boston Children,s Hospital, and Christopher M. Fischer, MD, ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- People ... likely to attempt suicide, whether or not they also ... a new study. "Clinicians who are seeing patients ... at increased risk of suicide," said study co-author Mark ... Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Cedar Rapids, IA (PRWEB) May 22, 2013 ... inspirational theatre piece Handicap This! The performance promotes ... pursuing their dreams. The Handicap This! performance will be ... Linn Mar High School auditorium. Tickets for Handicap ... , Handicap This! helps audiences measure the level to ...
Breaking Medicine News(10 mins):Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2
... ... ... Advocate Christ Medical Center and Hope Children’s Hospital was awarded the Morehead Apex Workplace ... the Ritz-Carlton in Charlotte, N.C. , , ,Christ Medical Center and Hope Children’s Hospital ...
... lead to new birth control for men , WEDNESDAY, April ... proteins called PLA2s play a vital role in sperm function ... The findings could improve understanding of male infertility and lead ... infertility. , In one study, Japanese researchers found that the ...
... ... except if the girls in the salon chair are battling cancer or other serious illness. Then, ... ... at the Tipperary Hair Salon in Beverly Hills, California, approximately 35 such girls and their sisters ...
... ... District to Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- ... and chillers and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler ...
... 28, 2010 Many of the world,s leading experts in ... first-of-its-kind conference in Kansas City to change the way childhood ... hosted by Children,s Mercy Hospitals and Clinics, is to apply ... unique make-up of pediatric patients and improve outcomes. ...
... ... about supporting you after the sale when you believe you need to return an item. ... with complete confidence knowing that their purchase can be returned for a replacement or a ... ...
Cached Medicine News:Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 2Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 3Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 2Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 3Health News:The Acorn Aqua's Lead Free Bubbler 2Health News:Advances in personalized medicine take center stage 2Health News:National Allergy Supply, The Allergy Products Company Recommended By More Than 9,500 Doctors Nationwide, Announces 100% Unconditional Satisfaction Guarantee 2
All welded construction for strength and durability. Choice of stainless steel or chrome plated models. One forward leg with caster for increased mobility....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Ideal for surgical procedures, these portable stands fit into tight areas for easy instrument access. Designed for limited space environments. Adjustable height for comfortable use while sitting or s...
Medicine Products: